TNSN04001A1 - Association d'un antagoniste des recepteurs d'aldosterone et d'un inhibiteur de hmg-coa- reductase. - Google Patents
Association d'un antagoniste des recepteurs d'aldosterone et d'un inhibiteur de hmg-coa- reductase.Info
- Publication number
- TNSN04001A1 TNSN04001A1 TNP2004000001A TNSN04001A TNSN04001A1 TN SN04001 A1 TNSN04001 A1 TN SN04001A1 TN P2004000001 A TNP2004000001 A TN P2004000001A TN SN04001 A TNSN04001 A TN SN04001A TN SN04001 A1 TNSN04001 A1 TN SN04001A1
- Authority
- TN
- Tunisia
- Prior art keywords
- hmg
- coa
- association
- receptor antagonist
- aldosterone receptor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4747—Quinolines; Isoquinolines spiro-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Addiction (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Transplantation (AREA)
Abstract
METHODES ET ASSOCIATIONS NOUVELLES POUR LE TRAITEMENT ET/OU LA PROPHYLAXIE D'UN ETAT PATHOLOGIQUE CHEZ UN SUJET; LESDITES METHODES COMPRENANT L'ADMINISTRATION D'UN OU PLUSIEURS INHIBITEURS DE HMG-COA- REDUCTASE ET D'UN OU PLUSIEURS ANTAGONISTES DES RECEPTEURS D'ALDOSTERONE; ET LES ASSOCIATIONS COMPRENANT UN OU PLUSIEURS INHIBITEURS DE HMG-COA - REDUCTASE ET UN OU PLUSIEURS DESDITS ANTAGONISTES DES RECEPTEURS D'ALDOSTERONE.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30633601P | 2001-07-19 | 2001-07-19 | |
PCT/US2002/022896 WO2003007993A1 (fr) | 2001-07-19 | 2002-07-18 | Combinaison d'un antagoniste de recepteur d'aldosterone et d'un inhibiteur de reducatse d'hmg coa |
Publications (1)
Publication Number | Publication Date |
---|---|
TNSN04001A1 true TNSN04001A1 (fr) | 2006-06-01 |
Family
ID=23184836
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TNP2004000001A TNSN04001A1 (fr) | 2001-07-19 | 2004-01-06 | Association d'un antagoniste des recepteurs d'aldosterone et d'un inhibiteur de hmg-coa- reductase. |
Country Status (26)
Country | Link |
---|---|
US (2) | US20030149010A1 (fr) |
EP (1) | EP1406660B1 (fr) |
JP (1) | JP2004537553A (fr) |
KR (1) | KR20040023660A (fr) |
CN (1) | CN1537019A (fr) |
AP (1) | AP2004002951A0 (fr) |
AT (1) | ATE363917T1 (fr) |
BR (1) | BR0211274A (fr) |
CA (1) | CA2452678A1 (fr) |
CO (1) | CO5550464A2 (fr) |
DE (1) | DE60220522T2 (fr) |
EA (1) | EA200400029A1 (fr) |
EC (1) | ECSP044950A (fr) |
ES (1) | ES2286270T3 (fr) |
GE (1) | GEP20063811B (fr) |
IL (1) | IL159588A0 (fr) |
IS (1) | IS7093A (fr) |
MA (1) | MA27050A1 (fr) |
MX (1) | MXPA04000586A (fr) |
NO (1) | NO20040211L (fr) |
OA (1) | OA12983A (fr) |
PL (1) | PL367417A1 (fr) |
TN (1) | TNSN04001A1 (fr) |
UA (1) | UA76475C2 (fr) |
WO (1) | WO2003007993A1 (fr) |
ZA (1) | ZA200400288B (fr) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003901812A0 (en) * | 2003-04-15 | 2003-05-01 | Vital Health Sciences Pty Ltd | Phosphates of secondary alcohols |
BRPI0513677B8 (pt) * | 2004-07-30 | 2021-05-25 | Exelixis Inc | derivados de pirrol como agentes farmacêuticos |
EP1948600B1 (fr) | 2005-07-05 | 2014-04-16 | The President & Fellows Of Harvard College | Conjugues cibles sur le foie |
CN1310941C (zh) * | 2005-07-13 | 2007-04-18 | 南京大学 | 依普利酮的合成方法 |
AU2006313430B2 (en) * | 2005-11-08 | 2012-09-06 | Ranbaxy Laboratories Limited | Process for (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt |
GB0600967D0 (en) * | 2006-01-18 | 2006-03-01 | Imp Innovations Ltd | Methods |
WO2007106862A2 (fr) * | 2006-03-14 | 2007-09-20 | Kinemed, Inc. | Utilisation de statines pour stimuler une neurogenese |
EP2051696A2 (fr) * | 2006-08-18 | 2009-04-29 | Morton Grove Pharmaceuticals, Inc. | Compositions liquides stables de lévétiracétam et procédés |
FR2917975B1 (fr) * | 2007-06-26 | 2009-10-16 | Ceva Sante Animale Sa | Compositions et traitement de l'insuffisance cardiaque chez les animaux mammiferes non humains |
EP2135607A1 (fr) | 2008-06-18 | 2009-12-23 | Pharnext | Combinaison de pilocarpine et methimazol pour le traitement de la maladie de Charcot-MarieTooth et des troubles associés |
CN102316872B (zh) * | 2008-11-26 | 2016-12-21 | 萨蒂奥根制药公司 | 治疗肥胖症和糖尿病的胆汁酸再循环抑制剂 |
US9387206B2 (en) | 2009-11-03 | 2016-07-12 | Pharnext | Therapeutic approaches for treating Alzheimer's disease |
EP2322163A1 (fr) | 2009-11-03 | 2011-05-18 | Pharnext | Nouvelles approches thérapeutiques pour traiter la maladie d'Alzheimer |
MX337603B (es) * | 2009-11-30 | 2016-03-10 | Adare Pharmaceuticals Inc | Composiciones y tabletas farmaceuticas con recubrimiento compresible y metodos de fabricacion. |
ES2552657T3 (es) | 2010-05-26 | 2015-12-01 | Satiogen Pharmaceuticals, Inc. | Inhibidores del reciclado de ácidos biliares y saciógenos para el tratamiento de diabetes, obesidad, y afecciones gastrointestinales inflamatorias |
US9107983B2 (en) | 2010-10-27 | 2015-08-18 | Warsaw Orthopedic, Inc. | Osteoconductive matrices comprising statins |
US8877221B2 (en) | 2010-10-27 | 2014-11-04 | Warsaw Orthopedic, Inc. | Osteoconductive matrices comprising calcium phosphate particles and statins and methods of using the same |
US10010515B2 (en) | 2011-03-01 | 2018-07-03 | Pharnext | Therapeutic approaches for treating Parkinson's disease |
LT2727588T (lt) | 2011-03-01 | 2019-01-25 | Pharnext | Neurologinių sutrikimų terapija baklofeno ir akamprozato pagrindu |
US9248111B2 (en) | 2011-03-01 | 2016-02-02 | Pharnext | Therapeutic approaches for treating parkinson's disease |
US9241933B2 (en) | 2011-03-01 | 2016-01-26 | Pharnext | Compositions for treating amyotrophic lateral sclerosis |
DE102011015142A1 (de) * | 2011-03-17 | 2012-09-20 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | Agens zur Prophylaxe und Behandlung altersassoziierter Krankheiten und Störungen sowie zur Verlängerung der Lebensdauer |
WO2012170417A2 (fr) | 2011-06-06 | 2012-12-13 | Warsaw Orthopedic, Inc. | Procédés et compositions pour améliorer la croissance osseuse comprenant une statine |
PL2771003T3 (pl) | 2011-10-28 | 2017-10-31 | Lumena Pharmaceuticals Llc | Inhibitory ponownego wykorzystania kwasów żółciowych do leczenia pediatrycznych cholestatycznych chorób wątroby |
CN104023718B (zh) | 2011-10-28 | 2017-04-05 | 鲁美纳医药公司 | 用于治疗高胆血症和胆汁淤积性肝病的胆汁酸再循环抑制剂 |
MX2015013196A (es) | 2013-03-15 | 2016-04-15 | Lumena Pharmaceuticals Inc | Inhibidores de reciclaje de acidos biliares para el tratamiento de la enfermedad de reflujo gastroesofagico y esofago de barrett. |
CA2907230A1 (fr) | 2013-03-15 | 2014-09-18 | Lumena Pharmaceuticals, Inc. | Inhibiteurs du recyclage de l'acide biliaire pour le traitement de l'angiocholite sclerosante primaire et de la maladie inflammatoire de l'intestin |
US20150199491A1 (en) * | 2014-01-10 | 2015-07-16 | Critical Care Diagnostics, Inc. | Methods and systems for determining risk of heart failure |
CN114096268A (zh) | 2019-02-12 | 2022-02-25 | 米鲁姆制药公司 | 用于增加患有胆汁淤积性肝病的儿科受试者的生长的方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CZ294108B6 (cs) * | 1995-07-17 | 2004-10-13 | Warner@Lambertácompany | Krystalická forma I hydrátu atorvastatinuŹ tj@ semivápenaté soli kyseliny [R@}RgŹRgB]@}@fluorfenylB@betaŹdelta@dihydroxy@Q@}�@methylethylB@fenyl[}fenylaminoBkarbonyl]@�H@pyrrol@�@heptanové |
EP1498140A2 (fr) * | 1997-04-18 | 2005-01-19 | G.D. Searle & Co. | Procédé relatif à l'utilisation d'inhibiteurs de cyclooxygénase-2 dans la prévention des maladies cardiovasculaires |
GT199800126A (es) * | 1997-08-29 | 2000-01-29 | Terapia de combinacion. | |
US6638937B2 (en) * | 1998-07-06 | 2003-10-28 | Bristol-Myers Squibb Co. | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists |
UA74141C2 (uk) * | 1998-12-09 | 2005-11-15 | Дж.Д. Сірл Енд Ко. | Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти) |
WO2000062775A1 (fr) * | 1999-04-19 | 2000-10-26 | The Regents Of The University Of Michigan | Compositions et methodes destinees a augmenter la biodisponibilite de medicaments contenant un noyau de lactone |
-
2002
- 2002-07-18 UA UA2004010388A patent/UA76475C2/uk unknown
- 2002-07-18 CA CA002452678A patent/CA2452678A1/fr not_active Abandoned
- 2002-07-18 JP JP2003513598A patent/JP2004537553A/ja active Pending
- 2002-07-18 IL IL15958802A patent/IL159588A0/xx unknown
- 2002-07-18 PL PL02367417A patent/PL367417A1/xx not_active Application Discontinuation
- 2002-07-18 WO PCT/US2002/022896 patent/WO2003007993A1/fr active IP Right Grant
- 2002-07-18 AT AT02756521T patent/ATE363917T1/de not_active IP Right Cessation
- 2002-07-18 EA EA200400029A patent/EA200400029A1/ru unknown
- 2002-07-18 ES ES02756521T patent/ES2286270T3/es not_active Expired - Lifetime
- 2002-07-18 CN CNA028145577A patent/CN1537019A/zh active Pending
- 2002-07-18 KR KR10-2004-7000846A patent/KR20040023660A/ko not_active Application Discontinuation
- 2002-07-18 BR BR0211274-4A patent/BR0211274A/pt not_active IP Right Cessation
- 2002-07-18 MX MXPA04000586A patent/MXPA04000586A/es active IP Right Grant
- 2002-07-18 GE GE5410A patent/GEP20063811B/en unknown
- 2002-07-18 US US10/198,475 patent/US20030149010A1/en not_active Abandoned
- 2002-07-18 DE DE60220522T patent/DE60220522T2/de not_active Expired - Fee Related
- 2002-07-18 OA OA1200400005A patent/OA12983A/en unknown
- 2002-07-18 EP EP02756521A patent/EP1406660B1/fr not_active Expired - Lifetime
- 2002-07-18 AP APAP/P/2004/002951A patent/AP2004002951A0/en unknown
-
2003
- 2003-12-23 IS IS7093A patent/IS7093A/is unknown
-
2004
- 2004-01-06 TN TNP2004000001A patent/TNSN04001A1/fr unknown
- 2004-01-14 ZA ZA2004/00288A patent/ZA200400288B/en unknown
- 2004-01-15 MA MA27479A patent/MA27050A1/fr unknown
- 2004-01-16 NO NO20040211A patent/NO20040211L/no not_active Application Discontinuation
- 2004-01-19 EC EC2004004950A patent/ECSP044950A/es unknown
- 2004-01-19 CO CO04002848A patent/CO5550464A2/es not_active Application Discontinuation
-
2005
- 2005-08-18 US US11/206,499 patent/US20060003975A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
ATE363917T1 (de) | 2007-06-15 |
KR20040023660A (ko) | 2004-03-18 |
GEP20063811B (en) | 2006-05-10 |
IL159588A0 (en) | 2004-06-01 |
DE60220522D1 (de) | 2007-07-19 |
UA76475C2 (en) | 2006-08-15 |
ECSP044950A (es) | 2004-02-26 |
MXPA04000586A (es) | 2004-04-20 |
NO20040211L (no) | 2004-03-16 |
CA2452678A1 (fr) | 2003-01-30 |
US20060003975A1 (en) | 2006-01-05 |
ES2286270T3 (es) | 2007-12-01 |
CO5550464A2 (es) | 2005-08-31 |
AP2004002951A0 (en) | 2004-03-31 |
ZA200400288B (en) | 2005-06-29 |
PL367417A1 (en) | 2005-02-21 |
OA12983A (en) | 2006-10-13 |
IS7093A (is) | 2003-12-23 |
BR0211274A (pt) | 2004-08-03 |
US20030149010A1 (en) | 2003-08-07 |
WO2003007993A1 (fr) | 2003-01-30 |
JP2004537553A (ja) | 2004-12-16 |
EP1406660A1 (fr) | 2004-04-14 |
CN1537019A (zh) | 2004-10-13 |
EP1406660B1 (fr) | 2007-06-06 |
MA27050A1 (fr) | 2004-12-20 |
DE60220522T2 (de) | 2007-09-27 |
EA200400029A1 (ru) | 2004-08-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TNSN04001A1 (fr) | Association d'un antagoniste des recepteurs d'aldosterone et d'un inhibiteur de hmg-coa- reductase. | |
ATE311200T1 (de) | Verfahren und zusammensetzungen zur behandlung von allergischen zuständen mit pgd2 rezeptor antagonisten | |
ATE293989T1 (de) | Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten | |
ATE516305T1 (de) | Il-15-bindungsstelle für il-15-ralpha und spezifische il-15-mutanten mit wirkung als agonisten/antagonisten | |
TR200102021T2 (tr) | TWEAK ve TWEAK reseptörü antagonistleri ve bunların imünolojik bozuklukların iyileştirilmesi için kullanımları | |
EP2319527A3 (fr) | BAFF, ses inhibiteurs et leur utilisation pour moduler la réponse immunitaire des cellules B et des immunoglobulines | |
NZ595262A (en) | Use of il-23 and il-27 antagonists to treat autoimmune ocular inflammatory disease | |
TNSN01053A1 (fr) | Compositions nouvelles comprenant un agoniste partiel des recepteurs de nicotine et un agent analgesique | |
ATE433973T1 (de) | Azolylaminoazine als inhibitoren von proteinkinasen | |
DE59601122D1 (de) | N-(Benzofurazanyl)-Arylsulfonamide und ihre Analoge verwendbar als Endothelin-Rezeptor-Antagonisten | |
NO20013947L (no) | Krystallstruktur av cPLA2 og fremgangsmåter for å identifisere agonister og antagonister under anvendelse av samme | |
DE60236218D1 (de) | CCR5 Antagonisten verwendbar für die Behandlung von Aids | |
EA200200207A1 (ru) | Применение антагонистов cgrp и ингибиторов высвобождения cgrp для устранения приливов в период менопаузы | |
DE60009888D1 (de) | Substituierte 3-cyano-[1.7], [1.5] und [1.8]naphthyridininhibitoren von tyrosin kinasen | |
YU13301A (sh) | Muskarinski agonisti i antagonisti | |
ATE266420T1 (de) | Kombinationspräparat, das selektive nmda nr2b- antagonisten und cox-2 inhibitoren enthält | |
DE69915113D1 (de) | 5ht1 rezeptor antagonisten und ihre verwendung für die behandlung von depression | |
EA200601592A1 (ru) | Фармацевтическая композиция, содержащая ингибитор pde4 или pde3/4 и антагонист гистаминового рецептора | |
ME00549B (me) | Upotreba inhibitora il-18 za liječenje i/ili prevenciju srčanih oboljenja | |
SE0300445D0 (sv) | New combination | |
MXPA02012257A (es) | Uso de un antagonista de aldosterona para el tratamiento o profilaxis de efectos patogenicos mediados por aldosterona. | |
NO20013459D0 (no) | Anvendelse av agiotensin II reseptorantagonister ved behandling av akutt myokardinfarkt | |
NO20041595L (no) | Ny kombinasjon bestaende av en PDE4 inhibitor eller en PDE3/4 inhibitor i kombinasjon med en leukotrienreseptorantagonist for behandling av luftveislidelser | |
FR2865736B1 (fr) | Inhibiteurs de l'angiogenese, compositions les contenant et leur utilisation pour le traitement des maladies liees a une deregulation de l'angiogenese | |
ATE230265T1 (de) | Zusammensetzung von alpha-adrenergen antagonisten mit stickstoffoxiddonoren zur behandlung von sexualfunktionsstörungen bei frauen |